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Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall
survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant
regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell
death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a
clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC
and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to
standard of care adjuvant platinum-based chemotherapy.
Clinical trial registration: NCT04267848 (ClinicalTrials.gov)
Tweetable abstract: Non-small-cell lung cancer adjuvant platinum-based therapy is standard of care (SOC).
Including pembrolizumab may improve efficacy. A081801 (ACCIO) is a three-arm study: SOC versus sequential chemotherapy–pembrolizumab versus concurrent chemotherapy + pembrolizumab.
First draft submitted: 27 January 2021; Accepted for publication: 7 April 2021; Published online:
21 April 2021
Keywords: adjuvant chemotherapy • lung adenocarcinoma • lung squamous cell carcinoma • NSCLC

• pembrolizumab

Lung cancer overview
Lung cancer accounted for 1.76 million deaths worldwide in 2018 and claims more lives each year in the USA
than breast, colon and prostate cancers combined [1,2]. Although surgically resectable non-small-cell lung cancer
(NSCLC) is considered curable, many patients experience disease recurrence impacting survival [3]. Cisplatin-based
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adjuvant chemotherapy is the standard of care for stage IB (≥4 cm) – IIIA (per AJCC 7) NSCLC tumors, but
the absolute benefit is marginal [3]. A systemic therapy regimen that further reduces recurrence rates after surgical
resection of early stage NSCLC could significantly impact outcomes for a substantial number of patients.
Introduction to the trial

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National
Cancer Institute, National Clinical Trial Network clinical trial platform offering biomarker analysis for highrisk resected NSCLC to support randomized trials of novel adjuvant therapies [4]. ALCHEMIST includes a
screening trial (A151216, 5708 registered patients as of 5 October 2020) enrolling patients with completely
resected clinical stage IB (≥4 cm)–IIIA (per AJCC 7) NSCLC. Tissue and blood are collected for biomarker
testing including EGFR sequencing, ALK fluorescence in situ hybridization (FISH) and programmed death-ligand
1 (PD-L1) immunohistochemistry (IHC). Patients with EGFR mutations may enroll on a trial of adjuvant erlotinib
versus observation (A081105, 384 randomized as of 5 October 2020) while those with ALK fusions may enroll
on a trial of adjuvant crizotinib versus observation (E4512, 119 randomized as of 5 October 2020). A third trial
offering adjuvant nivolumab versus observation regardless of PD-L1 status (EA5142, 935 randomized) completed
enrollment on 19 October 2019. Each of these therapeutic trials enrolls patients after completion of adjuvant
chemotherapy.
Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody that binds to PD-1 on T cells, blocking the binding of PD-1
ligands (PD-L1 and PD-L2). Inhibition of the PD-1 pathway inhibits the downregulation of immune response
generated by PD-1 receptor signaling [5]. This limits T-cell suppression allowing for an antitumor response [6].
Pembrolizumab is now one of the more commonly utilized first-line therapeutic options in the treatment of
NSCLC either as a single agent or concurrent with chemotherapy [7–9].
A081801 (ACCIO)
Background & rationale

Substantial benefit has been noted with concurrent chemotherapy plus checkpoint inhibitor in the metastatic
setting [7,9,10]. To investigate the potential benefit of concurrent treatment with adjuvant chemotherapy and
pembrolizumab after complete resection of stage IB (>4 cm) – IIIA (per AJCC 7) NSCLC, a new trial within the
ALCHEMIST portfolio, activated as of 5 June 2020 enrolls patients prior to adjuvant chemotherapy. A three-arm
design, including enrollment to a sequential arm of adjuvant chemotherapy followed by pembrolizumab will also
allow for the potential to compare sequential to concurrent chemotherapy and pembrolizumab. Although multiple
other studies have enrolled, or are currently enrolling, a sequential arm, this study is the first to enroll prior to any
adjuvant chemotherapy. This difference in the time of enrollment has the potential to provide further perspective to
outcomes in this population. Trials enrolling after chemotherapy may select out only those with the best functional
status. At the same time, if one or more sequential immunotherapy studies mature and are reported, the trial will
be modified to drop an arm and continue enrollment only to the relevant arms.
Quality of life

Understanding the impact of treatment and symptoms on patients’ daily lives is essential to balance efficacy versus
safety of various treatments in clinical trials. In trials where there is a vast difference in outcomes between the
study arms, the impact on quality of life (QoL) may not be as relevant, as it would be expected that the improved
disease outcomes would naturally lead to better QoL. If the survival benefit detected is small but associated with
substantial health related QoL (HRQOL) worsening, some patients or clinicians may feel it is not worth the
tradeoff. Conversely, if a small survival benefit is detected with no decrement in HRQOL, then sentiments may be
different. Hence, collecting HRQOL information in this setting is important for informing multiple stakeholders,
including patients.
Patients with resected NSCLC tolerate four cycles of adjuvant chemotherapy well, and the additional side
effects are outweighed by the improvement in overall survival (OS) [11]. Pembrolizumab has been well tolerated in
metastatic NSCLC and either improved or maintained HRQOL compared with chemotherapy [12]. The present
trial, ACCIO, assigns patients to approximately 1 year of pembrolizumab, either starting concurrently with
platinum-based chemotherapy or sequentially. The cumulative adverse effects of extended therapy that may be
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Figure 1. Schema of the ACCIO trial including three arms. Pembrolizumab dosing is every 6 weeks. Sequential and
concurrent arms each include about 1 year of pembrolizumab.
PORT: Postoperative radiation therapy.

accepted in the metastatic setting, may lead to decreased compliance and acceptance of therapy in the adjuvant
setting.
Design
Study design
ACCIO (NCT04267848) is a randomized three-arm Phase III trial comparing the disease-free survival (DFS) and
OS as dual primary end points between the standard of care adjuvant chemotherapy followed by observation (arm
A), sequential adjuvant chemotherapy followed by pembrolizumab for 1 year (arm B) and combination adjuvant
chemotherapy plus pembrolizumab followed by pembrolizumab (arm C). Both experimental arms (B & C) include
the same duration of pembrolizumab (about 1 year). Individuals will be randomized based upon stratification
factors including: nonsquamous versus squamous, PD-L1 expression (≥50 vs <50%), smoking status (never vs
former/current) and pathological stage (IB and II vs IIIA). See Figure 1.
Prior studies have shown that the median DFS is generally around 42 months in this patient population treated
with standard of care adjuvant chemotherapy [3,13]. Reported median OS depends significantly on the stages
enrolled. ANITA trial included stage IB–IIIA and reported median OS of 65.7 months (39% stage III, 24% stage
II and 36% stage IB) [14]. IALT reported a 5-year OS of 44.5% with similar population of stage inclusion (40%
stage III, 24% stage II and 36% stage I) [15]. Studies such as E1505 had fewer stage III patients (29%) and a
predictably higher median OS (about 84 months).
Based on the AJCC clinical staging information for patients enrolled in the ALCHEMIST screening trial at
the time of protocol development (12% stage IB, 51% stage II and 37% stage IIIA), a projected median DFS
and OS of 42 and 66 months, respectively, for the standard of care arm (arm A) were considered reasonable. We
hypothesize that the addition of pembrolizumab (in both the combination and sequential experimental arms, arms
B and C) to the standard of care (arm A) will improve the median DFS to around 63 months and the median OS
to around 99 months. We think this is achievable based on data in stage IV NSCLC [7]. We will also compare the
adverse events, rate of drug discontinuation due to adverse events, and DFS and OS by different patient subgroups
of interest (defined by PD-L1 expression, tumor mutational burden status, etc.).
Enrollment to checkpoint inhibitor clinical trials in the adjuvant setting has occurred after completing chemotherapy. ACCIO is the first trial to enroll to an adjuvant regimen that includes a checkpoint inhibitor prior to any
adjuvant treatment, which may provide a more reliable comparison to adjuvant chemotherapy alone. The trial aims
to complete enrollment within a timeframe that is prior to significant data reporting of other accruing trials, but
the three-arm design also allows for dropping an arm that becomes less relevant if ongoing studies report data that
are definitive.
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Primary & secondary objectives

The primary objective of the study is to compare the DFS and OS as dual primary end points between standard of
care adjuvant chemotherapy (arm A) and combination chemotherapy and pembrolizumab (arm C), and standard
of care adjuvant chemotherapy (arm A) versus sequential chemotherapy followed by pembrolizumab (arm B) in
patients with resected (R0) stage IB (>4 cm)–IIIA NSCLC (7th edition). The three-arm design allows for a
secondary objective to compare the DFS and OS as dual primary end points between arms B and C in the defined
enrollment population. DFS is defined as the time from randomization to the first of either disease recurrence or
death from any cause. OS is defined as the time from randomization to death from any cause.
The study includes QoL objectives to compare patient-reported QOL 1 year after randomization as assessed
by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) between patients randomized to receive adjuvant chemotherapy followed by pembrolizumab (arm B),
and those randomized to receive adjuvant chemotherapy + observation (arm A) as well as compare combination
adjuvant chemotherapy plus pembrolizumab (arm C) to adjuvant chemotherapy + observation (arm A). Comparison of patient-reported QOL as assessed by the EORTC QLQ-C30 between patients randomized to receive
adjuvant chemotherapy + pembrolizumab concomitantly (arm C) and those randomized to receive adjuvant
chemotherapy + observation or adjuvant chemotherapy followed by pembrolizumab (arms A and B combined)
is also planned at completion of chemotherapy. The last QOL objective is to present longitudinal trajectories by
arm of patient-reported dyspnea and coughing as assessed by the Lung Cancer Modular Supplement (EORTC
QLQ-LC13).
Key eligibility criteria

Enrollment to A081801 (ACCIO) follows enrollment to A151216, which includes individuals that have undergone
an R0 resection of NSCLC (any histologic subtype) 7th edition staging IB (≥4 cm) – IIIA. Mediastinal adenopathy
that is incidentally detected by surgical specimen is eligible, but any known mediastinal adenopathy should not
be treated with up front resection nor enrolled in this trial. Eligible functional status includes Eastern Cooperative
Oncology Group (ECOG) Performance Status 0–1 after recovery from surgical resection. As part of A151216,
tumor samples are tested centrally for EGFR, ALK and PD-L1, and when positive for EGFR or ALK, may enroll to
A081105 and E4512, respectively. EGFR and ALK must be negative for enrollment of patients with nonsquamous
tumors to ACCIO. To enable more rapid enrollment, local testing is accepted for ACCIO, but central testing
on A151216 will also be performed. All patients must be eligible for standard of care adjuvant platinum-doublet
chemotherapy and treatment with checkpoint inhibitor. Enrollment must occur 30–77 days post surgery. Standard
laboratory values are required. PD-L1 testing must be completed prior to enrollment as this is a stratification factor,
and the following assays are considered acceptable: DAKO 22c3, DAKO 28–8, E1L3N or SP-263. Patients must
be age ≥18 years, have no ‘currently active’ second malignancy that is progressing or required treatment within
the last 3 years, excluding specified low-risk cancers that have undergone potentially curative therapy. No known
history of HBV or HCV is allowed.
Planned sample size & study period

The statistical analysis (further described later) includes 400 evaluable patients per arm for a total of 1200 evaluable
patients. To account for possible dropouts/nonevaluable patients, we plan to overaccrue by 5%, which will include
421 per arm and a total of 1263 patients randomized. Based on enrollment within the ALCHEMIST studies, we
expect accrual of at least 20 patients per month, which would result in full accrual around 5 years.
Dose & schedule of therapy

Arm A, the control arm, includes four cycles of standard of care adjuvant chemotherapy followed by observation.
The acceptable chemotherapy regimens are the same across all arms and include: cisplatin + pemetrexed, carboplatin + pemetrexed, cisplatin + gemcitabine and carboplatin + paclitaxel. All regimens are Q3 week cycles. Arm
B, sequential arm, includes four cycles of adjuvant chemotherapy followed by pembrolizumab for a total of about
1 year. Arm C, combination arm, includes four cycles of chemotherapy and concurrent pembrolizumab, followed
by pembrolizumab. Arms B and C each include the same duration of pembrolizumab treatment of about 1 year.
Pembrolizumab infusions are Q6 weeks for up to eight doses.
Currently postoperative radiation therapy (PORT) is allowed per investigator discretion and should be completed
after initial therapy (adjuvant chemotherapy) and prior to initiation (or continuation) of pembrolizumab in the
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‘continuance therapy’ timeframe of the protocol. Although controversial, in particular in light of the recent LUNG
ART results presented recently, PORT is considered for pathologically involved N2 nodes in the surgical specimen.
Although PORT may sometimes be considered for positive margin as well, any patients with postoperative positive
margins are not eligible for enrollment to ACCIO.
Efficacy end points

ACCIO includes dual primary end points in the primary objective comparing both DFS and OS between standard of
care adjuvant chemotherapy and combination adjuvant chemotherapy and pembrolizumab, and between standard
of care adjuvant chemotherapy and sequential adjuvant chemotherapy followed by pembrolizumab in surgically
resected NSCLC. Secondary objectives include a comparison of the DFS and OS of the sequential and combination
arms. Secondary end points also include adverse events and discontinuation rates of each experimental arm compared
with the control arm, a comparison of DFS and OS between the sequential and/or combination arms versus
standard of care chemotherapy alone by PD-L1 expression (tumor proportion score ≥50% vs tumor proportion
score <50%), and a comparison of DFS and OS between the sequential and/or combination arms versus standard
of care chemotherapy alone in patients that received at least two cycles of initial adjuvant chemotherapy.
QoL measures

The EORTC QLQ-C30, is a well-validated scale that assesses the overall QoL. It is composed of six functional
scales (physical, role, emotional, cognitive, social and global health status/QoL) and nine symptom scales/items
(fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial
impact). The EORTC-QLQ-LC13 is a 13-item lung cancer-specific questionnaire that is added to the EORTC
QLQ-C30 to obtain information about symptoms that are prevalent in lung cancer patients such as dyspnea,
cough and hemoptysis [16]. These measures will be collected at four time points during the trial: baseline (after
registration prior to first treatment), completion of chemotherapy, 1-year post randomization (+/− 4 weeks) and
2 years post randomization (+/− 4 weeks).
Statistical analyses

The primary goal is to compare each of the experimental arms to chemotherapy alone (arm A), where the alternative
hypothesis is that the pembrolizumab arms will each demonstrate improved DFS compared with the control arm.
400 evaluable patients will be accrued to each arm of the study using a 1:1:1 randomization scheme (1200 evaluable
total) to provide 90% power to detect an improvement in the median DFS from 42 to 63 months (hazard ratio
[HR] = 0.67), assuming a one-sided significance level of 0.005. The primary analyses will be two individual
comparisons (each experimental arm vs control) using a one-sided log-rank test. These analyses will take place
after an approximate 63-month accrual period and after 363 total DFS events have occurred across both arms
combined for each analysis (after a minimum follow-up of 30 months in all evaluable patients) or 5 years after
accrual completion (whichever comes first).
The testing of the two pairwise comparisons (each of the experimental arms to the chemotherapy alone arm)
will be done in a stepwise fashion. As the study design includes dual primary end points, a similar analysis will
be performed with OS. With 400 evaluable patients per arm, there is 90% power to detect an improvement in
the median OS from 66 to 99 months (HR = 0.67) assuming a one-sided significance level of 0.02. The primary
analyses will be a comparison of each of the two experimental arms to the chemotherapy alone arm using a one-sided
log-rank test for each analysis. These analyses will take place after an approximate 63-month accrual period and after
271 total OS events have occurred across both arms combined for each analysis (approximately after 30 months
of minimum follow-up in all evaluable patients) or 8 years after accrual completion, whichever comes first. The
testing of the two pairwise comparisons (each of the experimental arms to the chemotherapy alone arm) will be
done in the same manner as the DFS analysis, each with a one-sided alpha of 0.02.
Overall study design has one-sided alpha = 0.025 with 90% power to evaluate the first pairwise comparison of
interest (A vs C) for the dual primary end points of DFS and OS. If combination treatment is not found to be
significantly different than control for DFS or OS, the control treatment will be recommended. If combination
treatment is found to be significantly better for OS or DFS as compared with control, the next pairwise test will
compare sequential treatment versus control (arm B vs A), with an overall one-sided alpha = 0.025 and 90% power
for the dual primary end points of DFS and OS. If sequential treatment is not found to be significantly different
than control for OS or DFS, the combination treatment will be recommended. If sequential treatment found
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significantly better than control for OS or DFS, the preplanned secondary comparisons for comparing sequential
versus combination therapy will be undertaken.
We plan to conduct a secondary comparison of combination (arm C) versus sequential (arm B) strategies. We
recognize that during enrollment, there may be data reported from other sequential studies that could guide a
statistical plan to compare sequential to combination therapy. This could guide an amendment to adequately
design a comparison of these arms by an independent statistician. Currently there are no data to guide this analysis,
but we estimate the following for now: with 400 evaluable patients per arm based on an intent-to-treat analysis,
alpha = 0.05 combined (OS = 0.04; DFS = 0.01), power = 80% will enable us to detect an HR = 0.75 (comparing
combination to sequential therapy). Minimum follow-up of at least 4 years will be needed (325 events needed for
OS and 491 events needed for DFS).
All randomized patients with outcome data will be considered evaluable for the coprimary end point based on
the intent-to-treat principle. All randomized patients who withdraw consent prior to receiving treatment will be
excluded completely from all summaries and analyses. A secondary sensitivity analysis will assess the patients who
complete at least two cycles of chemotherapy. OS and DFS will be estimated using the Kaplan–Meier method,
where the stratified log-rank test will be used to compare the distributions across the treatment arms.
Pembrolizumab has been well tolerated, including in combination with chemotherapy. For example, in
KEYNOTE-189 (carboplatin and pemetrexed +/− pembrolizumab for nonsquamous NSCLC), there were 67.2
versus 65.8% grade 3+ adverse events in the pembrolizumab and control arms, respectively, reflecting the expected
toxicities of chemotherapy [7]. In this adjuvant study, the protocol specifies overview by a data-safety monitoring
board, and accrual will be temporarily suspended if at any time adverse events in the concurrent and/or sequential
arms are substantially higher than the control arm particularly related to grade 4+ nonhematologic events. An early
stopping rule is included for futility of DFS at 50 and 75% of the needed events.
Conclusion
NSCLC causes significantly more fatalities than any other cancer. Advances in treatment of resected early stage
NSCLC beyond platinum-based chemotherapy could significantly impact many lives. The ALCHEMIST platform
has successfully collected many samples from patients that have undergone resection of stage IB (≥4 cm)–IIIA
(per AJCC 7) NSCLC and enrolled to three adjuvant systemic therapy protocols. The latest ALCHEMIST trial,
A081801 (ACCIO), will evaluate the integration of immune checkpoint inhibitors and adjuvant systemic therapy in
resected NSCLC. Patients are being randomized to standard of care adjuvant platinum-based chemotherapy alone
versus sequential chemotherapy followed by pembrolizumab versus concurrent chemotherapy plus pembrolizumab.
By building off the ongoing ALCHEMIST platform, we hope to facilitate rapid enrollment to ACCIO across the
participating National Clinical Trial Network sites.
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Executive summary
Lung cancer overview
• Lung cancer accounted for 1.76 million deaths worldwide. Unfortunately, many individuals that undergo curative
intent treatment experience recurrence that often leads to mortality from lung cancer.
• Pembrolizumab is a humanized monoclonal antibody that binds to programmed cell death-1 on T cells, inhibiting
downregulation of immune response. This limited suppression of T cells allows for an antitumor response.
Pembrolizumab is one of the more commonly utilized first-line therapeutic options in the treatment of
non-small-cell lung cancer (NSCLC).
A081801 (ACCIO)
• Background & rationale: substantial outcome improvement has been demonstrated with concurrent
pembrolizumab in the metastatic setting. This leads to the logical hypothesis that inclusion of pembrolizumab in
the adjuvant setting will also improve outcomes. ACCIO also includes a health-related quality of life analysis with
the recognition that cumulative adverse effects of extended therapy that may be accepted in the metastatic
setting, may lead to decreased compliance and acceptance of therapy in the adjuvant setting.
• Design: ACCIO is a three-arm study under the ALCHEMIST umbrella that will evaluate both concurrent
chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of
care adjuvant platinum-based chemotherapy. A dual end point design of disease free and overall survival (OS) is
utilized, with a planned enrollment of 1200 evaluable patients.
• Primary and secondary objectives: the primary objective of the study is to compare the disease-free survival (DFS)
and OS as dual primary end points between the standard of care adjuvant chemotherapy (arm A) and
combination chemotherapy and pembrolizumab (arm C), and standard of care adjuvant chemotherapy (arm A)
versus sequential chemotherapy followed by pembrolizumab (arm B). The three-arm design allows for a
secondary objective to compare the DFS and OS as dual primary end points between the sequential (arm B) and
concurrent (arm C) arms. Secondary end points include patient-reported quality of life 1-year end points and
analysis based upon programmed cell death-ligand 1 (PD-L1) expression of ≥50% versus <50%.
• Key eligibility criteria: enrollment to ACCIO follows enrollment to A151216 including those with R0 resection of
NSCLC (any histologic subtype) 7th edition staging IB (≥4 cm) – IIIA. Inclusion criteria specifies functional status of
ECOG 0–1, EGFR and ALK negative, completed PD-L1 testing (all expression is eligible), no second malignancy
within the past 3 years (excluding specified low-risk cancers that have undergone potentially curative treatment).
Patients must be eligible for adjuvant chemotherapy and pembrolizumab along with other standard eligibility
criteria.
• Planned sample size and study period: statistical analysis include 400 evaluable patients per arm for a total of
1200 evaluable patients. Interim futility analyses are planned for DFS alone at 50 and 75% of the needed events.
• Dose and schedule: all chemotherapy regimens include the established dosing schedule. Pembrolizumab dosing is
600 mg every 6 weeks for up to eight doses in both the sequential and concurrent arms.
Conclusion
• NSCLC causes significantly more fatalities than any other cancer. Advances in the treatment of resected early
stage NSCLC could significantly impact many lives. The ALCHEMIST platform has successfully enrolled many
patients after surgical resection of NSCLC, and ACCIO is currently enrolling patients after R0 resection of NSCLC
with stage IB (>4 cm)–IIIA that are eligible for adjuvant chemotherapy and pembrolizumab who have not already
received any treatment other than resection. EGFR, ALK and PD-L1 results are required for enrollment. All NSCLC
subtypes and PD-L1 expression are eligible.
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